Supporting spin-outs, start-ups and sector investment

By addressing key barriers to investment we help shape credible, fundable ventures through strategic expertise and hands-on support.

Enabling researchers and early-stage companies to rapidly progress products and technologies toward the clinic, secure investment, and support company formation and growth.

Supporting spin-outs and start-ups

We support academics and early-stage cell and gene therapy companies to commercialise research through the development and funding of robust investable opportunities. UK academics can apply for in-kind support here.

Benefit from:

Investment readiness
  • Identification and mitigation of key barriers to investment
  • Tailored business strategy development and planning
  • Value inflection mapping to identify and plan around key milestones for the most investible pathway
  • Guidance on use of funds and alignment of funding with commercial and clinical objectives
  • Support for company formation and spin-out structuring
Technical and commercial de-risking to increase value
  • Integration of cross-functional expertise from an in-house team of regulatory, non-clinical and health economics experts
  • Design of translational development plans to support clinical progression
  • Support with experiment planning to strengthen data packages for investors
In-kind support

We provide in-kind support to academic researchers from UK universities, with support focused on company creation and early translation of therapeutics, therapeutic platforms and enabling technologies. 

Please complete this form to apply.  

Supporting sector investment

We also work with the venture capital community to understand the key requirements for investment, and can provide small amounts of pre-seed/seed funding to address these requirements, de-risk early technologies and make investment flow more readily. 

Benefit from:

Network and investor engagement
  • Access to an established network of early-stage life sciences investors
  • Supporting training and development of pitch decks
  • Facilitate strategic feedback from industry and investors to shape commercial direction
  • Collaboration with university technology transfer offices to identify and support high-potential academic teams
Direct investment
  • Equity and in-kind investments into early-stage companies
  • Pre-incorporation investments into academic-led projects 

News feed

Spliceor receives investment from the Cell and Gene Therapy Catapult as part of the Cross-Catapult Investment PilotSpliceor receives investment from the Cell and Gene Therapy Catapult as part of the Cross-Catapult Investment PilotPlurify and the Cell and Gene Therapy Catapult to develop technology that improves purity of cell therapiesPlurify and the Cell and Gene Therapy Catapult to develop technology that improves purity of cell therapiesStanding out: Defining the market for your new ATMP assetStanding out: Defining the market for your new ATMP assetAn effective team strategy for cell and gene therapy venturesAn effective team strategy for cell and gene therapy ventures

Health economics and market access

Support to develop robust pricing and reimbursement strategies established at the right stage of your product development.

Regulatory affairs

ATMPs face unique regulatory challenges. We support ATMP developers to address specific risks in their product development and satisfy the relevant national and international legislation and guidance.

Non-clinical support

We strive to help academics, start-ups, and therapy developers with bespoke strategies to ensure effective translation of novel therapies through the non-clinical phases towards clinical trials.

Working on a cell or gene therapy innovation challenge?

Contact us today to find out how we can support you.